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During the past two decades, several new hereditary renal cancers have been discovered but are not yet widely known. Hereditary
renal cancer syndromes can lead to multiple bilateral kidney tumors that occur at a younger age than that at which the
nonhereditary renal cancers occur. The aim of our work is to review the features of hereditary renal cancers, the basic principles
of genetic relevant to these syndromes, and the various histopathologic features of renal cancer. In addition, we will describe the
known familial syndromes associated with small renal masses.
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1. INTRODUCTION
The incidence of renal cell carcinoma is increasing. This
disease aﬀectsapproximately 150000 people annuallyworld-
wide, causing nearly 78000 deaths [1]. Of these cases,
approximately 4% are thought to be associated with auto-
somal dominant hereditary cancer syndromes [2].
Hereditary renal cancer diﬀers from sporadic renal can-
cer in several important respects. A hallmark of hereditary
renal cancer is that it is often multiple and bilateral.
These distinct forms of inherited epithelial kidney cancer
include von Hippel-Lindau disease (VHC), hereditary pap-
illary renal carcinoma (HPRC), Birt-Hogg-Dub´ e syndrome
(BHD), hereditary leiomyomatosis renal cell carcinoma
(HLRCC) and renal carcinoma associated with hereditary
paraganglioma [2]. The genes for each of these disorders
havebeenidentiﬁedbypositional cloningincluding theVHL
gene, the MET proto-oncogene, the BHD gene, the FH gene,
and the SDHB gene [2]. Recently, familial renal carcinoma
(FRC) has been described. Families with multiple members
with renal carcinoma who do not have one of the known
inherited forms of renal carcinoma are considered to have
FRC. FRC is currently a diagnosis of exclusion [3].
A small percentage of renal cell carcinomas (RCCs),
which are subclassiﬁed by histology into clear cell (75% of
cases), papillary (10–15%), and chromophobe (5%) RCCs,
and renal oncocytoma (3%–5%), are due to inherited cancer
syndromes [4]. Each inherited cancer syndrome, such as
VHL, HPRC and hereditary leiomyomatosis and renal cell
carcinoma (HLRCC), is characterized by the development
of speciﬁc histologic types of renal cancer [2]. For example,
aﬀected members of families with VHL syndrome frequently
develop clear cell RCCs, whereas patients with HPRC are
predisposed to develop type-1 papillary renal carcinomas
[5]. Patients with HLRCC, by contrast, develop aggressive
papillary type-2 renal carcinomas [6] (see Table 1).
The widespread use of body imaging in recent years
has led to a signiﬁcant increase in the incidence of renal
cell carcinoma (RCC). A distinction between benign and
m a l i g n a n ts m a l lr e n a lm a s s e sc a n n o tb em a d eb a s e do n
radiographic data alone and percutaneous renal mass biopsy
is still controversial [7]. Clinicians therefore, when con-
fronted with small renal masses, must carefully weight the
risks and beneﬁts of surgical removal [8].
Herein, we will review the features of hereditary renal
cancers, the basic principles of genetic relevant to these
syndromes, and the various histopathologic features of renal
cancer. In addition, we will describe the known familial
syndromes associated with small renal masses.
2. VON HIPPEL-LINDAU DISEASE
VonHippel-Lindau(VHL)diseaseisanautosomaldominant
syndrome that aﬀects multiple organ systems. Extrarenal
manifestations of VHL include central nervous system
hemangioblastomas, endolymphatic sac tumors, retinal
angiomas, pheocromocytomas, and pancreatic cysts and
tumors [9].2 Advances in Urology
Table 1: Characteristics of autosomal dominant (AD) forms of kidney cancer (adapted from Zbar et al. [3]).
Disease Gene Renal Tumor histology
VHL VHL Clear cell Ca
HPRC MET Papillary type 1
HLRCC FH Renal cell Ca, HLRC type
BHD BHD Chromophobe/hybrid oncocytic neoplasm/clear cell Ca
Renal cancer occurs in 25–45% of patients with VHL;
if cystic lesions are included in this estimate, the incidence
increases to over 60% [10] .A sr e n a lt u m o r si nV H Lt e n dt o
be multifocal and bilateral and unaﬀected renal tissue is at
risk for developing additional tumors [11], management of
these patients is a challenge. The primary goal of managing
patients with VHL is prevention of metastatic disease [9].
However, the capacity for CT to detect solid renal masses at
an earlier stage increases the importance of secondary goals,
such as preservation of renal function and maximization
of quality of life, by minimizing the number of surgical
procedures that patients must undergo [10].
In VHL, patients inherit a germline mutation of the VHL
gene on chromosome 3p25 [12]. The VHL gene encodes
pVHL, which is part of a complex (including elongin B/C
and CUL2) that targets the α-subunit of hypoxia-inducible
factors 1 and 2 (HIF1α and HIF2α) for ubiquitin-mediated
proteasomaldegradation.IfthesecondcopyoftheVHLgene
in a patient is inactivated, HIF1α and HIF2α accumulate.
This leads to an increased transcription of genes that encode
downstreamsubstratesofHIF1αandHIF2α,suchasvascular
endothelial growth factor, platelet-derived growth factor and
transforming growth factor-α (TGF-α). These molecules are
thought to be important in VHL tumorigenesis [13].
In the pre-CT era, strategies for managing VHL renal
tumors were often limited to watchful waiting or bilateral
nephrectomy with renal replacement therapy (dyalisis or
renal transplantation). The high historical rate of metastasis
(13–42%) [14], despite the generally low grade of VHL renal
tumors, makes watchful waiting an unappealing strategy.
Some researchers have advocated bilateral nephrectomy as
a means of removing all renal tissue at risk for tumor
development [15].
Performing bilateral nephrectomy necessitates renal
replacement therapy. Goldfarb et al. compared 32 patients
with VHL who underwent bilateral nephrectomy and subse-
quent renal transplantation with a matched cohort of renal
transplant recipients without VHL [16].
No signiﬁcant diﬀerences in graft survival or renal
function were observed between the two groups. Five deaths
ocurred in both groups; three in the VHL group were due to
metastatic disease. Five-year survival was 65%. The authors
concluded that renal transplantation was an eﬀective form of
renal replacement therapy for VHL patients with limited risk
of cancer recurrence [16].
Nephron-sparing surgery (NSS) has the potential to
preserve renal function while maintaining oncology eﬃcacy
for appropiately selected patients. Favorable results were
achieved in several cohorts of VHL patients undergoing NSS
[9].
Factors associated with successful NSS outcomes were
smalltumorsizeandlowtumorgrade;largertumors(>5cm)
had higher local recurrence and metastatic rates [17].
Even though many VHL patients are young and other-
wise healthy, the morbidity of hemodialysis and immuno-
suppression is signiﬁcant; ﬁve-year survivalrates fora cohort
of patients demographically similar to VHL patients were
71% on hemodialysis and 86% following renal transplanta-
tion [9].
Although salvage partial nephrectomy carries a high
rate of perioperative morbidity. However, more than three-
quarters of operated kidneys can be preserved with only
modest decreases in renal function. These patients are able
to avoid or postpone the associated morbidity of dialysis,
including some patients with solitary kidney. Oncological
outcomes are encouraging at intermediate followup with no
evidence of detectable metastatic disease [18].
Undergoing frequent surgeries for small renal masses is
notanappealingprospectforVHLpatients;anobservational
strategy in combination with NSS is more attractive.
A cohort of patients with VHL and renal masses were
observed until the largest tumor in a renal unit was 3cm
in diameter, at which time surgery was recommended.
The pattern of recurrence, bilaterality, and number of
tumors were not taken into consideration [14]. The rate of
metastases increases with increasing tumor size (Table 2).
The 3cm threshold is not an absolute threshold demar-
cating development of metastatic disease; rather it is a point
at which the risk of metastasis with the potential morbidities
of multiple procedures are balanced [9].
Because of the high rate of recurrence of renal tumors
in VHL and the diﬃculties associated with repeated renal
surgery, ablative technologies such as cryoablation and
radiofrequency ablation (RFA) have been valid alternatives.
Ablative procedures have been performed both laparoscopi-
cally and percutaneously [9].
The potential role of the heat-shock protein 90 inhibitor
17-allylamino-17-desmethoxy-geldanamycin in VHC is cur-
rently being evaluated in patients with small (2-3cm)
presurgical renal lesion. Inhibition of heat shock protein
90, a molecular chaperone of HIF, facilitates proteasomal
degradation of HIF [9]. These approaches, which target the
abnormal molecular pathways involved in VHL tumorigen-
esis, represent a potential future approach to treatment of
patients with both sporadic and VHL-associated clear-cell
kidney cancer.
NSS-bases approaches to management of VHL-
associated renal tumors, using a 3cm tumor size threshold
for recommendation of surgery, can provide good cancer
control while preserving renal function and minimizingJ. Hidalgo and G. Ch´ echile 3
Table 2: Comparision of tumor size and metastaes (adapted from Duﬀey et al. [19]).
Tumor Size (cm) Number of metastases Number of patients Percentage of patients with metastases
≤3.0 0 108 0
3.1–4.1 1 27 4
4.1–5.5 4 19 21
5.6–10.0 10 20 50
≥10.1 5 7 71
interventions. This type of strategy mandates diligent
screening and followup. More experience with minimally
invasive techniques is needed before their role in treatment
of VHL renal tumors can be deﬁned. Medical therapy with
new molecular-targeted agents is a promising potential
development in the management of VHL renal tumors
[9].
3. HEREDITARY PAPILLARY RENAL CARCINOMA
Papillary renal carcinoma (PRC) comprises 10% to 15% of
kidney epithelial tumors and it is histologically subdivided
into types 1 and 2 [20]. Hereditary papillary renal carcinoma
(HPRC) is an uncommon form of inherited kidney cancer
characterized by the predisposition to develop bilateral,
multifocal renal tumors with type-1 papillary architecture
[21]. Tumors show frequent trisomy of chromosome 7 and
they appear to arise from independent clonal events. HPRC
is associated with a mutation of the A MET proto-oncogene
at 7q31.3. The gene was originally described in 1984 but
was not linked with papillary renal cancer until 1997 [5].
This gene codes for a transmembrane receptor tyrosine
kinase. Mutations lead to activation of the MET protein,
which is also the receptor for hepatocyte growth factor. The
tumorsproducedinhereditarypapillaryrenalcancerarewell
diﬀerentiated type-1 papillary renal cancers [22].
Hereditary papillary renal tumors are generally hypovas-
cular and enhance only 10–30HU after intravenous admin-
istration of contrast material. This mirrors the experience
withsporadicpapillaryrenalcancers,whicharealsotypically
hypovascular. Papillary renal cancers can be mistaken for
cysts, and one must be careful to obtain accurate attenuation
measurementsbeforeandaftercontrastenhancement.Ultra-
sonographycanbeparticularlymisleadingwiththisdisorder,
because small tumors are often isoechoic [22].
Patients in HPRC have previously been reported to have
renal cancer on average in the sixth decade of life [21], later
than other inherited renal cancer syndromes such as VHL
disease, which often develops in patients in the third and
fourth decades of life. Schmidt and colleagues reported on
3 families with HPRC in which, individuals in HPRC are
at risk for bilateral, multifocal kidney cancer earlier in life
(second decade) [23]. In addition, this report emphasizes
that HPRC can be a lethal disease since a number of aﬀected
individualsinthesefamiliesdiedofmetastatickidneycancer.
Type-1 papillary renal carcinoma in patients with HPRC is a
malignant tumor that can be lethal if it is not detected and
treated early [23].
4. BIRT-HOGG-DUB´ E SYNDROME
Birt-Hogg-Dub´ e syndrome (BHD) is an autosomal domi-
nant cancer syndrome characterized by the development of
small dome-shaped papules on the face, neck, and upper
trunk (ﬁbrofolliculomas). In addition to these benign hair
follicle tumors, BHD confers and increases the risk of
renal neoplasia and spontaneous pneumothorax. The gene
has been mapped to chromosome 17p11.2 and recently
identiﬁed, expressing a novel protein called folliculin [24].
Recently, individuals with BHD syndrome were found to
have a seven-fold higher risk over the general population of
developing kidney neoplasms [25].
Unlike renal tumors in patients with other inherited
kidney cancer syndromes, renal tumors from BHD patients
exhibit a spectrum of histologic types, including chromo-
phobe (34%), oncocytoma (5%), clear cell (9%), papillary
(2%), and an oncocytic hybrid (50%) with features of
chromophobe RCC and renal oncocytoma [26]. Germline
mutations have been identiﬁed in a novel gene, BHD in
aﬀected family members [27]. BHD encodes a protein,
folliculin, which is named for the hallmark dermatologic
lesions found in BHD patients. All germline mutations
identiﬁed to date are frameshift or nonsense mutations
that are predicted to truncate folliculin, including insertions
or deletions of a tract of eight cytosines (C8) in exon
11 [27].
Pavlovich et al. [26] reported 130 solid renal tumors
resected from 30 patients with BHD in 19 diﬀerent families.
Preoperative CT demonstrated a mean of 5.3 tumors per
patient (range 1–28 tumors), the largest tumors averaging
5.7cmindiameter(±3.4cm,range1.2–15cm).Multipleand
bilateraltumorswerenotedatanearlyage(mean50.7years).
The resected tumors consisted predominantly of chromo-
phobe renal cell carcinomas (34%) or of hybrid oncocytic
neoplasms that had areas reminiscent of chromophobe renal
cell carcinoma and oncocytoma (50%). Twelve clear cell
(conventional) renal carcinomas (9%) were diagnosed. The
tumors were on average larger (4.7 ± 4.2cm) than the chro-
mophobe (3.0 ± 2.5cm)andhybridtumors(2.2 ± 2.4cm).
Microscopic oncocytosis was found in the renal parenchyma
of most patients, including the parenchyma of ﬁve patients
with evidence of clear cell renal cell carcinoma. These
ﬁndings suggest that microscopic oncocytic lesions may be
precursors of hybrid oncocytic tumors, chromophobe renal
cell carcinomas, and perhaps clear cell renal cell carcinomas
in patients with BHD syndrome.
The malignant nature of BHD associated renal tumors
has not been previously established. BHD associated kidney4 Advances in Urology
cancer has the potential to be a lethal disease based on family
histories of death from metastatic RCC in several patients
with BHD. Pavlovich and colleagues [28] suggest that BHD-
associated chromophobe and hybrid oncocytic RCC may
be of lesser malignant potential than BHD associated clear
cell RCC but these lesions cannot be considered completely
benign based on their cytomorphology and the known
occasionally malignant behavior of chromophobe tumors.
In families in which multiple members are found to have
chromophobe or hybrid oncocytic renal carcinomas, BHD
should be considered. Eﬀorts are currently underway to
determine why some BHD families have kidney cancer and
others do not [28].
Urological surgeons who treat patients with BHD should
keep in mind the potential for perioperative pneumothorax
in these patients. A high percent of patients with BHD is
aﬀected with pulmonary cysts (almost 90%) and more than
20% have a history of spontaneous pneumothorax.
To address the mutation status of the BHD gene in
tumorsfromBirt-Hogg-Dub´ epatients, Vocke andcolleagues
[29] analized a panel of 77 renal tumors by direct DNA
sequenceanalysis.Tumorsamples,aswellasmatchednormal
samples, were obtained from 12 aﬀected members of BHD
families after renal surgery. BHD patients were often found
to have bilateral, multifocal tumors and underwent staged
bilateral partial nephrectomies, providing tumor samples
for the study. The entire coding region of BHD (exons
4–14) was sequenced in each tumor sample, following
polymerase chain reaction (PCR) ampliﬁcation. Their data
showed that the tumors from a given BHD patient have
diﬀerent second hits. These observations strongly suggest
that multiple renal tumors from some BHD patients are
independent, clonal events, each arising from a separate and
unique second mutation in the BHD gene. However, some
tumors with mixed histologies shared a common somatic
mutation in the distinct histologic regions within each
tumor. This ﬁnding suggests that in some cases, a somatic
second hit precedes histologic diversiﬁcation within a single
tumor. The molecular mechanism that drives these events is
unknown. These results document the high frequency and
wide spectrum of second mutations, which strongly support
a tumor suppressor role of BHD. Inactivation of both copies
of BHD ocurred in several histologic types of renal tumors,
suggesting that BHD may act at an early stage of renal
oncogenesis. Further understanding of the mechanism of
BHD-induced tumorigenesis awaits functional studies of the
follicullin protein [29].
In addition, BHD is an autosomal dominant hereditary
cancer syndrome, in which aﬀected individuals are at risk for
cutaneous ﬁbrofolliculomas, pulmonary cysts, spontaneous
pneumothorax, and kidney tumors. Almost 30% of aﬀected
patients with BHD examined had solid renal tumors.
Because of the spectrum of renal tumor histologies found
in patients with BHD, their variable natural history, and
the risk of recurrent renal tumors in such patients, it is
important for urologists to be aware of this syndrome. The
current management approach for BHD associated renal
tumors is to perform nephron sparing surgery when possible
[28].
5. HEREDITARY LEIOMYOMATOSIS AND
RENAL CELL CANCER
A hereditary form of kidney cancer referred to as hereditary
leiomyomatosis and renal cell cancer (HLRCC) has been
identiﬁed, in which aﬀected family members have cutaneous
leiomyomas, uterine ﬁbroids, and/or kidney cancers [6].
The renal malignancies that develop in HLRCC families are
often metastatic at presentation and are a signiﬁcant cause
of mortality in these families. Analysis of families with this
disorder has identiﬁed the responsible gene locus as FH
[30]. This gene encodes fumarate hydratase (FH), an enzyme
that is part of the mitochondrial Krebs or tricarboxylic acid
(TCA) cycle, located at 1q42.2-42.3. The gene is inherited in
an autosomal dominant manner. The mechanism by which
alterations in FH lead to HLRCC remains to be determined,
but it apparently involves increased cellular dependence on
glycolysis.
The reason why FH alterations are associated with tumor
formation in HLRCC families is not entirely clear at this
time. It seems intuitively that a cell that lacks functional
FH (and hence has a defective TCA cycle) would be at
a metabolic disadvantage, particularly with regard to the
eﬃciencyofnutrientcatabolism.HLRCCisnot,however,the
only hereditary cancer syndrome associated with a defective
enzyme of the Krebs cycle. Germline mutations in the
succinate dehydrogenase complex have been identiﬁed that
predisposetothedevelopmentofhereditaryparagangliomas.
Succinate dehydrogenase catalyzes the conversion of succi-
natetofumarate—thestepintheTCAcyclethatimmediately
precedes the reaction catalyzed by FH. Mutations in subunits
B, C, and D of the succinate dehydrogenase complex have all
been linked to hereditary paraganglioma.
The extrarenal manifestations of HLRCC were described
previously [6]. The most frequent manifestation is uterine
leiomyomas in aﬀected females (75% to 98%). More than
90%ofthewomenunderwentmyomectomyorhysterectomy
and approximately half had undergone hysterectomy by age
of 30 years. Cutaneous leiomyomas are ﬁrm, skin-colored
to light brown or red papules. They may be segmental
and multifocal, and are mainly found on the trunk and
extremities. They may be painful. Mean age at onset of
cutaneous manifestations is 25 years (range 10 to 47) [31].
The incidence is 36% to 85%.
There are several unique aspects to HLRCC-associated
renal tumors that diﬀerentiate them from other inherited
formsofkidneycancer.WhereastumorsinVHL,HPRC,and
BHDtwinsareoftenmultifocalandinvolvethe2kidneys[2],
renal tumors in patients with HLRCC may be solitary.
Toro et al. [31] reported 19 patients with heredi-
tary leiomyomatosis and renal cell cancer associated renal
tumors. Individual considered aﬀected by HLRCC had
greater than 10 skin lesions clinically compatible with
leiomyoma and a minimum of 1 lesion histologically con-
ﬁrmed as leiomyoma or tested positive for a germline FH
mutation. Patients underwent precontrast and postcontrast
CT of the chest, abdomen, and pelvis after informed consent
was provided. Renal lesions were considered indeterminate
if they were too small (less than 1cm in diameter) to beJ. Hidalgo and G. Ch´ echile 5
accurately classiﬁed as solid or cystic. Only lesions 1cm
or greater and enhancing more than 20HU that were
predominantly solid were considered renal tumors.
For HLRCC they did not adhere to the strategy of
expectant management for tumors less than 3cm, as we
previously described for other hereditary kidney cancer
s y n d r o m e s ,s u c ha sV H L ,H P R C ,o rB H D[ 2, 19, 28].
HLRCC-associated renal tumors appear to represent a
signiﬁcantly more aggressive type of renal cancer than that
in patients with VHL, HPRC, or BHD. Even small HLRCC
renal tumors are associated with nodal and metastatic
disease. In the reported study [32], they often treat patients
with VHL, HPRC, and BHD and small (less than 3cm)
tumors expectantly, recommending surgery in many when
the largest lesion reached 3cm. To their knowledge no
patients with VHL, HPRC, or BHD who presented with
tumors less than 3cm have had metastatic disease using
this clinical management approach [14, 19]. Because of the
aggressive nature of the renal cancer in HLRCC in the
current study [32] and the potential for small tumors to
metastasize, the data suggest that small lesions prospec-
tively identiﬁed in patients at risk for HLRCC should
not be managed by an expectant, nonsurgical strategy.
Experience with nephron sparing surgery in the setting of
HLRCC is limited to date and no formal recommendations
regarding the most eﬃcacious surgical approach (radical
versus partial nephrectomy) for clinically localized renal
tumors can be made at this time, nephron-sparing surgery
could be potentially as curative as radical nephrectomy
as has been demonstrated in nonhereditary forms of
RCC.
A family history of renal tumors, especially causing death
at a young age, early hysterectomy in women due to symp-
tomatic ﬁbroids, cutaneous leiomyomas, and importantly
smalltumorswithalymphnodeormetastaticdiseaseburden
out of proportion to tumor size should alert clinicians
to the possibility of HLRCC. Renal tumors found in this
syndrome, which are frequently described as papillary type
II or collecting duct histology, appear to be signiﬁcantly
more aggressive than other forms of hereditary renal cancer.
Because of limited experience with screening and treating
these patients, optimal management strategies remain to
be deﬁned. However, the early experience with HLRCC-
associated renal carcinoma suggests that extreme caution
is warranted. Observational strategies that are suitable for
select patients with small renal masses associated with other
hereditary renal cancer syndromes are not appropriate for
patients with HLRCC. HLRCC-associated kidney cancer
is markedly diﬀerent from kidney cancer associated with
other hereditary cancer syndromes, such as VHL, HPRC,
and BHD. These patients should be evaluated and treated
cautiously [32].
6. RENAL CARCINOMA ASSOCIATED WITH
HEREDITARY PARAGANGLIOMA
Germline mutations of the genes encoding succinate dehy-
drogenase subunits B (SDHB) and D (SDHD) predispose to
paraganglioma syndromes type-4 (PGL-4) and type-1 (PGL-
Table 3: Clinical and pathological subtypes of familial renal
carcinoma (adapted from Zbar et al. [3]).
(1) Single clear cell renal carcinomas
(2) Bilateral multiple clear cell renal carcinomas, without VHL
(3) Single clear cell renal carcinomas and renal oncocytomas∗
(4) Single clear cell renal carcinomas and papillary renal
carcinomas∗∗
(5) Single and multiple renal oncocytomas without the other
clinical features of BHD syndrome
(6) Single or multiple bilaterally renal carcinomas but not HPRC
or HLRCC
(7) Other
∗Families with some members aﬀected with single clear cell
renal carcinomas and other members aﬀected with single renal
oncocytomas
∗∗Families with one member aﬀected with single clear cell renal
carcinoma and another member aﬀected with single clear cell
renal carcinoma and another member aﬀected with papillary renal
carcinoma
1), respectively. In both syndromes, pheochromocytomas
as well as head and neck paragangliomas occur; however,
details for individual risks and other clinical characteristics
are unknown.
Theparagangliomasyndromeshavebeenrelativelynewly
delineated as unique entities. Although paraganglioma has
been clinically recognized for more than 40 years, only
in the last 4 years they have been classiﬁed based on
molecular genetics: SDHD mutations predispose to PGL-1,
mutations in an unidentiﬁed gene on chromosome 11 to
PGL-2, SDHC mutations to PGL-3, and SDHB mutations
to PGL-4. In Neumann et al. report [33], consistent with
the apparently aggressive nature of SDHB dysfunction, 5
mutation carriers in their study were also found to have
extra paraganglial malignancies (e.g., renal cell carcinoma
and thyroid papillary carcinoma). Kidney carcinomas are
considered oncocytic tumors (replete with mitochondria)
and thus, the involvement of a mitochondrial complex
II gene in kidney carcinogenesis may be explained. The
apparently more aggressive nature of the tumors in SDHB
mutation carriers may be postulated to be a consequence
of the prevention of assembly of the catalytic complex
that normally comprises SDHA and SDHB, thus leav-
ing only complexes of the structural SDHC and SDHD
moieties.
Mutations in other genes can be causes of hereditary
renal carcinoma. These genes include hepatocyte nuclear
factor 1 α and 1 β, the tuberous sclerosis genes and and
SDHB [33].
7. FAMILIAL RENAL CARCINOMA
There are several interrelated questions when approaching
the family with multiple members with renal carcinoma.
The ﬁrst issue is determining whether the family is aﬀected
with one of the known inherited forms of renal carcinoma.
The diagnosis of one of the known inherited forms of renal6 Advances in Urology
Table 4: FRC versus autosomal dominant (AD) forms of kidney cancer (adapted from Zbar et al. [3]).
Disease Inheritance mode Age at onset Tumor multiciplicity Histology
FRC Complex Late Single varied
VHL AD Adolescence Bilat, multiple Clear cell
HPRC AD 40–49 years Bilat, multiple Papillary type 1
BHD AD 30–39 years Bilat, multiple Chromophobe/hybrid oncocytic
HLRCC AD 10–20 years Single or multiple Renal cell Ca, HLRCC type
carcinoma is based on clinical evaluation and DNA testing.
Families with 2 or more members with renal carcinoma who
do not have one of the known inherited forms of renal
carcinoma are considered to have FRC. Recently, Zbar et
al. [3], reported a study in which familial renal carcinoma
(FRC) was described and provisionally clasiﬁed (Table 3).
They evaluated 141 at risk asymptomatic relatives of aﬀected
individuals from 50 families with 2 or more members with
renal carcinoma. Histology slides of renal tumors from
aﬀected family members were reviewed and were not found
to be VHL, BHD, HLRCC, or HPRC. At risk, members
from renal carcinoma families were screened for occult
renal neoplasms by renal ultrasound and computerized
tomography. DNA from selected families was tested for
germline mutations of known renal carcinoma genes when
clinically indicated and constitutional cytogenetic analysis
was performed to search for germline chromosome alter-
ations. This collection of renal carcinoma families represents
a well-studied population from which families with the
4 well-known causes of inherited renal carcinoma were
removed from the study.
Findings suggested that, when confronted with a family
with FRC, careful analysis should be performed of the family
to search for known causes of inherited renal carcinoma
(Table 4). The manifestations of hereditary leiomyoma renal
carcinoma may be particularly diﬃcult to identify. The most
likely cause of aggressive, early onset FRC was hereditary
leiomyoma renal cell carcinoma. In general, bilateral mul-
tiple renal carcinomas in more than 1 family member are
highly suggestive of an autosomal dominant form of renal
carcinoma. If there is a suggestion of hereditary renal cancer,
appropriate biopsies and scans should be performed and
DNA mutation studies should be performed to conﬁrm the
diagnosis.
8. CONCLUSIONS
Small renal masses in the case of renal cancer syndromes
must be studied from a particular point of view because
hereditary renal cancers can lead to multiple and/or bilateral
kidney tumors. The primary goal of managing patients with
familial renal syndromes is prevention of metastatic disease.
Nephron sparing surgery has the potential to preserve renal
function while maintaining oncology eﬃcacy for selected
patients. In some syndromes, it is appropiate to develop a
watchful waiting attitude, 3cm size tumor seems to be the
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